Research programme: RNAi therapeutics - Arrowhead Pharmaceuticals

Drug Profile

Research programme: RNAi therapeutics - Arrowhead Pharmaceuticals

Alternative Names: ARC AMG1; ARC HIF2; ARC-F12; ARO ANG3; ARO APOC3; ARo Lung1; ARO-AMG1; ARO-ENaC; ARO-F12; ARO-Lung1

Latest Information Update: 24 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mirus Bio Corporation
  • Developer Arrowhead Pharmaceuticals; Roche Madison
  • Class Antifibrotics; Antihyperlipidaemics; Antineoplastics; Antithrombotics; Cardiovascular therapies; Small interfering RNA
  • Mechanism of Action Endothelial PAS domain-containing protein 1 inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders; Cystic fibrosis; Hereditary angioedema; Hypertriglyceridaemia; Liver cancer; Lung cancer; Renal cell carcinoma; Solid tumours; Thromboembolism
  • No development reported Hyperlipidaemia; Respiratory tract disorders

Most Recent Events

  • 24 Sep 2018 Arrowhead Pharmaceuticals plans to file a clinical trial application (CTA) for ARO-ENaC for Cystic fibrosis, in 2019
  • 24 Sep 2018 Arrowhead Pharmaceuticals plans to file a clinical trial application (CTA) for Hypertriglyceridaemia and dyslipidaemias for ARO APOC3 and ARO ANG3 respectively by the end of 2018
  • 21 May 2018 Preclinical trials in Cystic fibrosis in USA (Inhalation) prior to May 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top